Table S1. Clinical and biological data of the patients included in the study. Table S2. Tagmented DNA library and post-enrichment pooled library yield and average size. Table S3. Lane-specific sequencing quality parameters (cluster density, percentage of clusters passing filter, total number or reads passing filter and percentage of bases with quality ⼠Q30). Table S4. Sample-specific sequencing quality scores (percentage of bases with quality ⼠Q30 and average Q-score). Table S5. List of somatic somatic disease-related mutations (non-synonimous and nonsense SNVs and InDels located in the coding region and splicing sites). Variants are flagged as shared if present both in FF and FFPE samples, FP if called only in FFPE and FN if called o...
Detailed information of all somatic mutations in targeted amplicon sequencing (TAS), including cover...
Cohorts, ethnicity, and tumor stage of samples used for WES, SNP array, and qPCR. Table S2. Regions ...
Table S3. Somatic and germline mutations identified in primary tumor and metastasis tissues from 5 p...
Table S1. Sequencing parameters for 3 samples with the highest and 3 samples with the lowest sequenc...
Table S1. Sequencing metrics for libraries prepared with both Agilent SureSelect XT v.5 and Roche Ni...
Systematic approach to study exome capture variability in exome-sequencing (A) Three-generation pedi...
Panel description and references. Table S2. Cutting areas of ESD-resected specimens (n=19) by laser ...
Table S7. Mean coverage achieved by Agilent SureSelect and Roche NimbleGen libraries within 90 PCR-c...
Supplementary tables. Table S1. Cancer genes in detected amplification regions. Table S2. Cancer gen...
Table S5. Quality information of the WES technology, with the mean target coverage, and the % of bas...
Table S5. Quality information of the WES technology, with the mean target coverage, and the % of bas...
Clinicopathological data for MOTs. Table S2. Summary of whole exome sequencing statistics. Table S3....
All supplementary tables merged. 1: List of all identified SiMPRes. 2: All novel genes that contain ...
Figure S1. Schematic overview of the computational pipeline to identify somatic mutations in NG-TAS ...
Table S2. Filtered variants detected in three or more patients. Chromosome, start, end - genome coor...
Detailed information of all somatic mutations in targeted amplicon sequencing (TAS), including cover...
Cohorts, ethnicity, and tumor stage of samples used for WES, SNP array, and qPCR. Table S2. Regions ...
Table S3. Somatic and germline mutations identified in primary tumor and metastasis tissues from 5 p...
Table S1. Sequencing parameters for 3 samples with the highest and 3 samples with the lowest sequenc...
Table S1. Sequencing metrics for libraries prepared with both Agilent SureSelect XT v.5 and Roche Ni...
Systematic approach to study exome capture variability in exome-sequencing (A) Three-generation pedi...
Panel description and references. Table S2. Cutting areas of ESD-resected specimens (n=19) by laser ...
Table S7. Mean coverage achieved by Agilent SureSelect and Roche NimbleGen libraries within 90 PCR-c...
Supplementary tables. Table S1. Cancer genes in detected amplification regions. Table S2. Cancer gen...
Table S5. Quality information of the WES technology, with the mean target coverage, and the % of bas...
Table S5. Quality information of the WES technology, with the mean target coverage, and the % of bas...
Clinicopathological data for MOTs. Table S2. Summary of whole exome sequencing statistics. Table S3....
All supplementary tables merged. 1: List of all identified SiMPRes. 2: All novel genes that contain ...
Figure S1. Schematic overview of the computational pipeline to identify somatic mutations in NG-TAS ...
Table S2. Filtered variants detected in three or more patients. Chromosome, start, end - genome coor...
Detailed information of all somatic mutations in targeted amplicon sequencing (TAS), including cover...
Cohorts, ethnicity, and tumor stage of samples used for WES, SNP array, and qPCR. Table S2. Regions ...
Table S3. Somatic and germline mutations identified in primary tumor and metastasis tissues from 5 p...